11 Dec QurAlis’ selective Kv7 opener, a drug candidate for ALS, demonstrates up to 20-fold increase in potency and dramatic reduction in side effects compared to Retigabine in preclinical models
QurAlis' announces the results of extensive pre-clinical studies on its lead program for ALS patients: QRA-244 shows comparable effects to retigabine and dramatic reductions in side effects....